The Latest Breaking News from CEPI

Since COVID was first reported in December 2019, there have been more than 775 million recorded infections and more than 7 million deaths from the disease. This makes COVID the seventh-deadliest pandemic in recorded history.

It uses the same vaccine technology as the Oxford Covid jab.

CEPI allocated $375,000 just a few days after the WHO declared the disease a global health emergency.

Four separate cases registered; searches carried out at 40 locations

Sydney University is hoping to develop a COVID-19 vaccine that will protect against all known variants of concern, as well as future strains of the virus.

Funding is to support development of a ‘variant-proof’ vaccine candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity Inc (NASDAQ:VAXX) will co-fund the ongoing global Phase 3 trial of Vaxxinity's next-generation UB-612 COVID-19 vaccine candidate. The candidate is under development as a heterologous – or 'mix-and-match' – booster dose.  CEPI will provide up to $9.25 million in funding. The Phase 3 trial, which began in…

The company behind a COVID-19 vaccine touted as a key tool for the developing world will miss a target for giving doses to the U.N.-backed effort to deliver shots to poorer countries